Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health
NCT ID: NCT01890889
Last Updated: 2013-11-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
150 participants
INTERVENTIONAL
2013-07-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Upon completion of the pre-study screening, and after having received an explanation of the requirements, risks and benefits, and completing the informed consent interview with the research coordinator, subjects will execute a written informed consent. Subjects will be randomly assigned to one of three study groups.
Relevant Background Information.
A factor leading to development of vascular disease, a leading cause of death in industrialized nations, is elevated serum cholesterol. It is estimated that 19% of Americans between the ages of 20 and 74 years of age have high serum cholesterol. However, in an analysis of 10,000 test results in our database from subjects similar to those who are likely to participate in this study, we found 37% of subjects had TC scores between 200 and 250 and 10.3% above 250.
The most prevalent form of vascular disease is arteriosclerosis, a condition associated with the thickening and hardening of the arterial wall. The regulation of whole-body cholesterol homeostasis involves the regulation of intestinal cholesterol absorption, cellular cholesterol trafficking, a modulation of cholesterol biosynthesis, bile acid biosynthesis, steroid biosynthesis and the catabolism of the cholesterol-containing plasma lipoproteins. Regulation of intestinal cholesterol absorption has proven to be an effective means by which to regulate serum cholesterol levels.
Ad-Chol-Pre (ACP) is a functional food ingredient designed to inhibit cholesterol absorption. ACP is a freeze dried defatted egg powder containing specific Anti-NPCIL1 (Niemann-Pick C1-like 1) IgY. NPC1L1 is known as a biological target of the cholesterol-uptake inhibitor, Ezetimibe. In previous unpublished pilot studies examining the safety and efficacy of ACP include:
* ACP was shown to produce a statistically inhibition of \[3H\]-Cholesterol absorption from 50 ug/ml (P\<0.05) in NPC1L1 over-expressing HepG2 cell lines as compared to an inhibition of 10ug/ml with Ezetimibe alone.
* I preliminary unpublished animal studies, ACP was shown to significantly inhibit radiolabelled cholesterol. ACP was found to significantly lower total cholesterol (38% \~56%) and LDL cholesterol (46\~57%) in bloods from animals fed who had been fed a high fat diet for 6 weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ad-Chol-Pre
A functional food ingredient designed to inhibit cholesterol absorption. ACP is a freeze dried defatted egg powder containing specific Anti-NPCIL1 (Niemann-Pick C1-like 1) IgY. NPC1L1 is known as a biological target of the cholesterol-uptake inhibitor, Ezetimibe.
Ad-Chol-Pre
Half-dose Ad-Chol-Pre
A half-dose of the active comparator in arm one is administered. A functional food ingredient designed to inhibit cholesterol absorption. ACP is a freeze dried defatted egg powder containing specific Anti-NPCIL1 (Niemann-Pick C1-like 1) IgY. NPC1L1 is known as a biological target of the cholesterol-uptake inhibitor, Ezetimibe.
Half-dose Ad-Chol-Pre
Capsule containing inactive component of defatted egg yolk
Placebo capsule is filled with defat egg yolk only without specific IgY which is anti-NPC1L1 IgY, designed to look and taste the same as the active product capsule, but does not contain the active component.
Defatted egg yolk without the active ingredient of the other two interventions
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ad-Chol-Pre
Half-dose Ad-Chol-Pre
Defatted egg yolk without the active ingredient of the other two interventions
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* have a total cholesterol level between 200 mg/dL and 250mg/dL
* have a LDL level between 100 mg/dL and 160 mg/dL
* not have allergic reactions to eggs or egg products
* not have consumed cholesterol-lowering drugs within 2 months of starting the study
* agree to follow the requirements of the study as set forth in this Informed Consent
* agree to withdraw from the study if becoming pregnant during the study.
Exclusion Criteria
* are under 18 years of age;
* have a total cholesterol level below 200 mg/dL or above 250 mg/dL
* have a LDL level below 100 mg/dL or above 160 mg/dL
* have allergic reactions to eggs or egg products
* have consumed cholesterol-lowering drugs within 2 months of starting the study
* are pregnant or nursing;
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Integrative Health Technologies, Inc.
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gilbert R Kaats
Dr. Gilbert R. Kaats, PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gilbert R Kaats, PhD FACN
Role: PRINCIPAL_INVESTIGATOR
Integrative Health Technologies, Inc.
Harry G Preuss, MD MACN
Role: STUDY_CHAIR
Georgetown University Medical Center, Dept of Biochemistry, Medicine and Pathology
Sidney J Stohs, PhD
Role: STUDY_DIRECTOR
Dean Emeritus, Creighton University Health Sciences Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Integrative Health Technologies
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Patricia l Keith, BBA
Role: primary
Mike E Gale, BS
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
065
Identifier Type: -
Identifier Source: org_study_id